In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
The in vitro activities of ABT-773 were evaluated against 324 strains of gram-positive bacteria, including multidrug-resistant Staphylococcus spp. and Enterococcus spp. ABT-773 had lower MIC ranges, MICs at which 50% of isolates are inhibited (MIC(50)s), and MIC(90)s than erythromycin or clindamycin for almost all isolates tested. The MICs of ABT-773 were also lower than those of quinupristin-dalfopristin (Q-D) for methicillin-susceptible Staphylococcus aureus, Rhodococcus spp., and Streptococcus spp., while the MICs of Q-D were lower than those of ABT-773 for methicillin-resistant S. aureus and Enterococcus faecium, including vancomycin-resistant isolates.
Singh
K V
KV
Center for the Study of Emerging and Re-emerging Pathogens, The University of Texas Medical School, Houston, Texas 77030, USA. Kavindra.Singh@uth.tmc.edu
Malathum
K
K
Murray
B E
BE
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D048628:Ketolides; D008826:Microbial Sensitivity Tests; D014769:Virginiamycin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D048628:Ketolides; D014769:Virginiamycin; C113825:quinupristin; D002981:Clindamycin; D004917:Erythromycin; C405499:cethromycin